Literature DB >> 22020917

Combination DLL4 with Jagged1-siRNA can enhance inhibition of the proliferation and invasiveness activity of human gastric carcinoma by Notch1/VEGF pathway.

Hua-Wen Sun1, Chong Wu, Hai-Yan Tan, Qiu-Shuang Wang.   

Abstract

BACKGROUND/AIMS: To evaluate the effects of adenovirus- mediated gene transfer of DLL4 and Jagged1 siRNA on proliferation and invasion of SGC7901 cells by Notch/ VEGFR pathway.
METHODOLOGY: Plasmid of DLL4 and Jagged1 siRNA were constructed and transfected into SGC7901 cells. siRNA and endostatin (VEGF inhibitor) were designed as the control group. The mRNA and protein expressions of DLL4 and Jagged1 were respectively detected with RT-PCR and western blotting. In order to find out the changes of proliferation and invasion power of SGC7901 cell lines, we analyzed the data by MTT, Boyden chamber and evaluated apoptosis of cell with flow cytometry. We treated BALB/C nude mice with DLL4 and Jagged1-siRNA, and tumor control rate (%) in nude mice was calculated.
RESULTS: DLL4 and Jagged1 siRNA transfections specifically down-regulated the corresponding mRNA and protein levels in SGC7901 cells. The experiment of permeated artificial basal membrane showed that the invasion power of SGC7901 cell lines were on the decline after treatment of Ad-DLL4- Jagged1-siRNA (12.23±3.12 vs. 78.38±17.38, p<0.05). The values of 490nm wavelength light absorption were different in the five groups. The number of alive cells in the group of DLL4-Jagged1-siRNA was lower than others in the 6th d (0.77±0.01 vs. 3.00±0.11 p<0.05). The apoptosis rate of transfected DLL4 and Jagged1 group with FACS were 18.07%±0.98±1.78 and there were significant differences between treated and control groups (18.07%±0.98 vs. 1.08%±0.23, p<0.01). The tumor transplantation experiment in BALB/C nude mice showed that intratumoral injection of DLL4 and Jagged1 siRNA could inhibit tumor growth.
CONCLUSIONS: DLL4 and Jagged1 siRNA gene therapy mediated by adenovirus may be useful for inhibiting growth and invasion of SGC7901 through a Notch/VEGFR pathway. These results provided a novel therapeutic target in preventing gastric cancer cell invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22020917     DOI: 10.5754/hge11484

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Effect of dihydroarteminin combined with siRNA targeting Notch1 on Notch1/c-Myc signaling in T-cell lymphoma cells.

Authors:  Lanfen Huo; Wenwen Wei; Shaoling Wu; Xindong Zhao; Chunting Zhao; Hongguo Zhao; Lingjie Sun
Journal:  Exp Ther Med       Date:  2018-01-23       Impact factor: 2.447

2.  Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.

Authors:  Eisuke Kobayashi; Arun K Iyer; Francis J Hornicek; Mansoor M Amiji; Zhenfeng Duan
Journal:  Clin Orthop Relat Res       Date:  2013-03       Impact factor: 4.176

3.  [Over-expression of human Notch ligand Delta-like 3 promotes proliferation of human gastric cancer cells in vitro].

Authors:  Bingxin Hu; Jianbin Ye; Xiaomei Qiu; Yanqing Lin; Danlin Wu; Junjie Wen; Meiqun Luo; Lijun Ning; Yan Li; Yunshan Ning
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

Review 4.  The Role of DLLs in Cancer: A Novel Therapeutic Target.

Authors:  Meng-Xi Xiu; Yuan-Meng Liu; Bo-Hai Kuang
Journal:  Onco Targets Ther       Date:  2020-05-07       Impact factor: 4.147

5.  Delta-like ligand 4 in hepatocellular carcinoma intrinsically promotes tumour growth and suppresses hepatitis B virus replication.

Authors:  Areerat Kunanopparat; Jiraphorn Issara-Amphorn; Asada Leelahavanichkul; Anapat Sanpavat; Suthiluk Patumraj; Pisit Tangkijvanich; Tanapat Palaga; Nattiya Hirankarn
Journal:  World J Gastroenterol       Date:  2018-09-14       Impact factor: 5.742

Review 6.  The notch ligand JAGGED1 as a target for anti-tumor therapy.

Authors:  Demin Li; Massimo Masiero; Alison H Banham; Adrian L Harris
Journal:  Front Oncol       Date:  2014-09-25       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.